



(51) International Patent Classification:

C07D 209/94 (2006.01) *A61P 29/00* (2006.01)
A61K 31/403 (2006.01) *A61P 37/06* (2006.01)

(21) International Application Number:

PCT/US2011/000153

(22) International Filing Date:

27 January 2011 (27.01.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/336,835 27 January 2010 (27.01.2010) US

(71) Applicant (for all designated States except US): **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MONTALBAN, Antonio, Garrido** [ES/US]; 10339 Azuaga Street, No. 213, San Diego, CA 92129 (US). **BUZARD, Daniel, John** [US/US]; 14494 Janal Way, San Diego, CA 92129 (US). **DeMattei, John, Aldo** [US/US]; 8521 Clatsop Lane, San Diego, CA 92129 (US). **GHARBAOUI, Tawfik** [US/US]; 2340 Lomica Place, Escondido, CA 92029 (US). **JOHANNSEN, Stephen, Robert** [US/US]; 4437 Mentone Street, No. 3, San Diego, CA 92107 (US). **KRISHNAN, Ashwin, M.** [US/US]; 11023 Cedarcrest Way, San Diego, CA 92121 (US). **KUHLMAN, Young, Mi** [US/US]; 10840 Scripps Ranch Blvd., No. 301, San Diego, CA 92131 (US). **MA, You-An** [US/US]; 12820 Oakfield Way, Poway, CA 92064 (US). **MARTINELLI, Michael, John** [US/US]; 12860 Baywind Point, San

Diego, CA 92130 (US). **SATO, Suzanne, Michiko** [US/US]; 11819 Miro Circle, San Diego, CA 92131 (US). **SENGUPTA, Dipanjan** [US/US]; 9121 Togan Avenue, San Diego, CA 92129 (US).

(74) Agents: **SPRUCE, Lyle, W.** et al.; Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, CA 92121 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF



(57) Abstract: The present invention relates to processes and intermediates useful in the preparation of of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

